Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration

NCT01467271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2019-02-04

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to prospectively estimate the incidence of Nephrogenic Systemic Fibrosis (NSF) in patients with moderate to severe renal impairment after administration of Dotarem®

Conditions

  • Renal Insufficiency

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Pierre Desché, MD · Guerbet

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States
  • Argentina
  • Belgium
  • Colombia
  • France
  • Germany
  • Italy
  • South Korea
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467271 on ClinicalTrials.gov